β2 microglobulin serum levels and prediction of survival in AL amyloidosis

Amyloid

Volumn 9, Issue 4, 2002, Pages 242-246

  Zerbini, Cristiano A F ^a,b   Anderson, Jennifer J ^a   Kane, Kelly A ^a   Ju, Shyr Te ^a   Campistol, Jose M ^a,c   Simms, Robert W ^a   Cohen, Alan S ^a   Skinner, Martha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL HELIÓPOLIS   (Brazil)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

AL amyloidosis; ELISA; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLOOD LEVEL; CARDIOMYOPATHY; CLINICAL FEATURE; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0036971077     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120209114100     Document Type: Article

References (30)

1. Berggård I and Bearn AG (1968). Isolation and properties of a low molecular weight B2 globulin occurring in human biological fluids. J Biol Chem 243, 4095-4103
2. 2-microglobulin and alloantigens coded for by the major histocompatibility complexes of the rat and the guinea pig. Scand. J Immunol 6, 1063-1069
3. Cresswell P, Springer T, Strominger JL, Turner MJ, Grey HM and Kubo RT (1974). Immunological identity of the small subunit of HL-A antigens and b2-microglobulin and its turnover on the cell membrane. Proc Nat Acad Sci (Wash) 71, 2123-2127
4. Buja LM, Khoi NB and Roberts WC (1970). Clinically significant cardiac amyloidosis: clinicopathologic findings in 15 patients. Am J Cardiol 26, 394-405
5. 2-microglobulin and the acquired deficiency syndrome in a low incidence area. JAMA 253, 43-44
6. 2-microglobulin and immunodeficiency in a homosexual man. N Engl J Med 307, 1402-1403
7. 2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet 339, 1436-1440
8. Cassuto JP, Krebs BJ, Viot G, Dujardin P and Maseyeff R (1978). B2-microglobulin, a tumour marker of lymphoproliferative disorders. Lancet 2, 950
9. Child JA and Kushwaha MR (1984). Serum beta-2-microglobulin in lymphoproliferative and myeloproliferative disease. Haematol Oncol 2, 391-401
10. 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7, 1518-1527
11. 2-microglobulin in low-grade lymphoma. Ann intern Med 14, 855-860
12. 2-microglobulin in chronic lymphocytic lekaemia. Scand J Haematol 24, 174-180
13. 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. Acta Haematol 64, 79-86
14. Rodriguez J, Cortes J, Talpaz M, O'Brien S, Smith TL, Rios MB and Kantarjan H (2000). Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res 6:147-152
15. Bjerrum OW and Plesner T (1985). Beta-2-microglobulin: a valuable parameter of stage, prognosis and response to treatment in myelomatosis. Scand J Haematol 35, 20-22
16. 2-microglobulin as a prognostic indicator in myelomatosis. Brit J Cancer 47, 111-114
17. 2-microglobulin in myelomatosis: potential value in stratification and monitoring. Brit J Cancer 42, 510-515
18. 2-microglobulin levels in multiple myeloma. Europ J Cancer Clin Oncol 19, 1361-1364
19. 2-microglobulin in multiple myeloma: relation to presenting features and clinical status. Europ J Cancer Clin Oncol 18, 59-66
20. 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer 52, 1-6.
21. Cohen AS and Jones LA (1992). Amyloid and amyloidosis. Curr Opin Rheumatol 44, 94-105
22. Falk RH, Comenzo RL and Skinner M (1997). The systemic amyloidoses. New Engl J Med 337(13), 898-899
23. Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C and Kayne H (1987). Survival of patients with primary amyloidosis. Colchicine treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 82, 1182-1190
24. Kyle RA and Greipp PR (1983). Amyloidosis. Clinical laboratory features in 229 cases. Mayo Clin Proc 58, 665-683
25. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR and Gertz MA (1999). Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant 23, 1261-1266
26. Gertz MA, Kyle RA, Greip PR, Katzman JA and O'Fallon WM (1990). Beta2-microglobulin predicts survival in primary systemic amyloidosis. Amer J Med 89, 609-614
27. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA and Cohen AS (1996). Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100, 290-298
28. Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53, 457-481
29. Gehan EA (1965). Generalized Wilcoxon test for comparing arbitrrary singly cenored samples. Biometrika 52, 203-223
30. Cox DR (1972). Regression models and life tables. J Stat Soc (Ser B) 34, 187-202